Status:
UNKNOWN
Nasal IL 1 Beta ,IL 3 Level and Their Effects in COPD Patients
Lead Sponsor:
Assiut University
Conditions:
Copd Patients
Eligibility:
All Genders
18-70 years
Brief Summary
Chronic obstructive pulmonary disease is associated with systemic and local inflammation. exposure to harmful gases and particles play important role in initiating the inflammatory processes leading t...
Detailed Description
. COPD patients asscioted with upper airway disease either high symptoms or low symptoms according to The 22-item Sino Nasal Outcome Test .Data will be collected through: History and examination of th...
Eligibility Criteria
Inclusion
- We included patients according to the following inclusion criteria:
- age ≥ 40 years
- History of smoking \> ten pack-years of tobacco
- Post- bronchodilator Forced Expiratory Volume 1 s (FEV1)/Forced Vital Capacity (FVC) index \<0.70.
Exclusion
- self-reported or physician- diagnosed asthma and reversibility for beta 2 agonist above 400 ml and 15% from baseline FEV1
- \-
Key Trial Info
Start Date :
September 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT05980611
Start Date
September 1 2023
End Date
December 1 2024
Last Update
August 8 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.